Ixabepilone (Ixempra) — CPB 0869 | AETNA Coverage Update

Aetna modified CPB 0869 covering ixabepilone (Ixempra) billing, effective September 26, 2025. Here's what billing teams need to know before submitting J9207 claims.

Aetna, a CVS Health company, updated its ixabepilone (Ixempra) coverage policy under CPB 0869, effective September 26, 2025. This policy governs HCPCS J9207 (injection, ixabepilone, 1 mg) and the infusion administration codes 96413 and +96415. The policy is narrowly scoped to breast cancer — and if your team bills ixabepilone for anything else, you're heading toward a claim denial.

Quick-Reference Table

Aetna Ixabepilone Coverage Criteria and Medical Necessity Requirements 2025

The Aetna ixabepilone coverage policy under CPB 0869 Aetna system limits medical necessity approval to breast cancer only. Three pathways get you to a covered claim. Each one has real documentation requirements you need to pull before billing.

Pathway 1: HER2-negative disease, single agent. The member must have HER2-negative locally advanced, recurrent, or metastatic breast cancer — or disease with no response to preoperative systemic therapy. Bill J9207 as a single agent. No combination regimen required.

Pathway 2: HER2-positive disease with trastuzumab. The member must have HER2-positive recurrent or metastatic disease — or no response to preoperative systemic therapy. Ixabepilone must be used in combination with trastuzumab (J9355). Both agents need to appear on the claim.

Pathway 3: Combination with capecitabine (J8522). This is the most documentation-intensive pathway. Two sub-criteria must both be met. First, the member must have failed both an anthracycline and a taxane, or the cancer must be taxane-resistant with further anthracycline therapy contraindicated. Second — and this is where a lot of claims fall apart — the member's AST (CPT 84450) must be no greater than 2.5 times the upper limit of normal (ULN), ALT (CPT 84460) no greater than 2.5 times ULN, and bilirubin no greater than 1 times ULN.

That liver function threshold isn't a soft guideline. Aetna treats it as a hard stop. Document those lab values in the chart and have them ready for prior authorization submission. If your practice doesn't run 84450 and 84460 in-house, confirm the reference lab results are in the record before the auth request goes in.

Continuation of therapy requires ongoing documentation. Aetna considers continued ixabepilone medically necessary when there's no unacceptable toxicity and no disease progression on the current regimen. Beyond 12 weeks, the threshold tightens: stable disease requires tumor size within 25% of baseline. After 12 weeks, "stable" has a specific meaning here — make sure your oncologist documents tumor measurements against baseline in each clinical note.

Prior authorization is the practical reality for oncology biologics at this price point. Ixabepilone reimbursement under J9207 carries significant per-claim dollar value. Expect Aetna to require prior auth on initial approval and to scrutinize continuation requests. Build your auth workflow around the three pathways above and have HER2 status, prior treatment documentation, and current liver function labs ready at submission.

Aetna Ixabepilone Exclusions and Non-Covered Indications

The non-covered list under CPB 0869 is long. Aetna considers ixabepilone experimental, investigational, or unproven for a wide range of solid tumors and CNS malignancies beyond breast cancer.

Specifically excluded indications include: cervical cancer, colorectal cancer, endometrial cancer, fallopian tube cancer, gastric cancer, medulloblastoma, meningioma, non-small-cell lung cancer, osteosarcoma, ovarian cancer, and pancreatic cancer — among others. This is not a complete list; the policy language says "not an all-inclusive list."

One separate hard exclusion matters for billing teams: Aetna considers ixabepilone not medically necessary for members who have experienced a severe (CTC grade 3/4) hypersensitivity reaction to medications formulated with Cremophor EL or its derivatives — for example, polyoxyethylated castor oil. If a member has this reaction history, the claim won't pass medical necessity review regardless of breast cancer diagnosis. Confirm allergy history before submitting.

The ICD-10 codes tied to this policy include C16.x (gastric), C18.x (colon), C25.x (pancreatic), C34.x (lung), and others in the experimental category. These codes are in Aetna's system, but claims paired with J9207 and a non-breast diagnosis will hit denial. If you see those diagnosis codes on an ixabepilone order, stop before billing.

Coverage Indications at a Glance

Aetna Ixabepilone Billing Guidelines and Action Items 2025

These are the concrete steps your billing team needs to take before the September 26, 2025 effective date — and on every claim going forward.

CPT, HCPCS, and ICD-10 Codes for Ixabepilone Under CPB 0869

Covered HCPCS Code (When Selection Criteria Are Met)

Key ICD-10-CM Diagnosis Codes

The breast cancer ICD-10 codes that support J9207 coverage are not reproduced here because the policy data does not list specific covered breast cancer codes — only the experimental/non-covered codes. Map your claims to the appropriate C50.x codes for breast cancer based on your payer's standard ICD-10 crosswalk.

The following ICD-10 codes appear in this policy tied to non-covered or experimental indications. Do not pair these with J9207 claims:

Additional non-covered ICD-10 ranges exist in the policy for ovarian, endometrial, cervical, fallopian tube, and CNS malignancies. The full code list runs to 140 ICD-10-CM codes. Review the complete policy at CPB 0869 Aetna before finalizing your diagnosis crosswalk.